VJHemOnc is committed to improving our service to you

COMy 2020 | Evidence supporting lenalidomide for high-risk smoldering myeloma patients

VJHemOnc is committed to improving our service to you

Sagar Lonial

Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the controversies in myeloma research. Two large Phase III trials have shown that early intervention with lenalidomide is highly beneficial for high-risk patients. A Spanish 10 year follow up study also indicated that early intervention improved survival. Therefore, high-risk patients should be enrolled in clinical trials and, if trial trials cannot continue, it would be reasonable to give patients short courses of lenalidomide. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter